宣泰医药 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	512.0M	300.0M	248.0M	315.0M	319.0M
Revenue Growth %	70.7%	21.0%	-21.3%	-1.3%	--
Total Revenue	512.0M	300.0M	248.0M	315.0M	319.0M
Cost Of Revenue	247.0M	132.0M	71.2M	69.0M	59.0M
+Gross Profit	265.0M	168.0M	176.8M	246.0M	260.0M
Gross Margin %	51.8%	56.0%	71.3%	78.1%	81.5%
Total Operating Cost	386.0M	248.0M	182.0M	223.0M	208.0M
Selling Expenses	10.4M	8.2M	6.1M	6.0M	7.3M
Admin Expenses	44.9M	35.8M	37.8M	39.7M	49.4M
Rd Expenses	84.9M	74.0M	76.0M	104.0M	75.8M
Finance Expenses	-6.3M	-7.2M	-8.5M	2.8M	10.9M
+Operating Income	144.0M	69.0M	99.1M	121.0M	142.0M
Operating Margin %	28.1%	23.0%	40.0%	38.4%	44.5%
Non Operating Income	5,600	128,100	3,200	33.0M	40,300
Non Operating Expenses	1.8M	3.1M	1.7M	5.3M	123,600
Investment Income	12.0M	11.4M	21.8M	4.2M	24.9M
Fair Value Change Income	--	--	--	457,400	--
Asset Disposal Income	--	82,100	155,500	--	43,100
Asset Impairment Loss	-1.6M	1.5M	-2.6M	1.0M	2.2M
Other Income	6.5M	6.0M	11.9M	23.9M	6.2M
Income Before Tax	142.0M	66.0M	97.5M	149.0M	142.0M
Income Tax	14.4M	4.9M	4.5M	14.1M	19.0M
+Net Income	128.0M	61.1M	92.9M	135.0M	123.0M
Net Margin %	25.0%	20.4%	37.5%	42.9%	38.6%
Net Income Attributable	128.0M	61.1M	92.9M	135.0M	123.0M
Eps Basic	0.28	0.13	0.22	0.33	0.30
Eps Diluted	0.28	0.13	0.22	0.33	0.30

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	226.0M	642.0M	763.0M	512.0M	434.0M
Trading Financial Assets	508.0M	--	--	--	--
Accounts Receivable	104.0M	65.9M	64.3M	40.4M	26.4M
Notes Receivable	--	--	--	446,100	--
Notes And Accounts Receivable	104.0M	65.9M	64.3M	40.8M	26.4M
Prepayments	13.1M	17.9M	28.6M	13.9M	16.3M
Inventory	102.0M	84.6M	29.4M	40.4M	41.8M
Total Current Assets	976.0M	952.0M	954.0M	619.0M	546.0M
Long Term Equity Investment	64.4M	64.2M	49.1M	27.4M	7.9M
Fixed Assets	--	256.0M	101.0M	106.0M	96.4M
Fixed Assets Total	264.0M	256.0M	101.0M	106.0M	96.4M
Construction In Progress	--	15.4M	154.0M	4.7M	9.3M
Construction In Progress Total	80.8M	15.4M	154.0M	4.7M	9.3M
Intangible Assets	21.7M	27.6M	32.5M	41.2M	51.6M
Long Term Deferred Expenses	918,300	1.2M	2.0M	3.2M	3.8M
Total Non Current Assets	477.0M	410.0M	379.0M	247.0M	193.0M
Total Assets	1.5B	1.4B	1.3B	866.0M	739.0M
Accounts Payable	20.7M	14.5M	9.2M	8.0M	7.2M
Advance Receipts	--	--	--	--	--
Contract Liabilities	30.4M	47.6M	56.1M	46.5M	95.5M
Total Current Liabilities	103.0M	90.7M	90.1M	89.5M	143.0M
Total Non Current Liabilities	77.1M	60.6M	65.0M	71.1M	33.9M
Total Liabilities	180.0M	151.0M	155.0M	161.0M	176.0M
Paid In Capital	453.0M	453.0M	453.0M	408.0M	408.0M
Capital Reserve	514.0M	513.0M	513.0M	179.0M	171.0M
Surplus Reserve	32.2M	24.6M	22.8M	16.1M	3.3M
Retained Earnings	310.0M	220.0M	188.0M	102.0M	-20.0M
Equity Attributable	1.3B	1.2B	1.2B	705.0M	562.0M
Total Equity	1.3B	1.2B	1.2B	705.0M	562.0M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	525.0M	323.0M	241.0M	275.0M	416.0M
Tax Refunds Received	15.8M	4.5M	5.4M	6.1M	6.2M
Total Operating Cash Inflow	557.0M	339.0M	263.0M	361.0M	431.0M
Cash Paid For Goods	254.0M	185.0M	47.9M	66.1M	95.7M
Cash Paid To Employees	88.0M	74.2M	70.4M	68.8M	57.2M
Taxes Paid	20.9M	5.7M	14.5M	7.2M	16.5M
Total Operating Cash Outflow	427.0M	326.0M	190.0M	215.0M	221.0M
Operating Cash Flow	130.0M	13.0M	73.2M	146.0M	210.0M
Total Investing Cash Inflow	2.2B	3.2B	2.0B	748.0M	160.0M
Total Investing Cash Outflow	2.7B	3.3B	2.2B	813.0M	186.0M
Investing Cash Flow	-484.0M	-108.0M	-200.0M	-64.2M	-25.9M
Dividends And Interest Paid	27.9M	28.1M	--	--	--
Debt Repayments	--	--	--	--	--
Total Financing Cash Inflow	--	--	390.0M	--	--
Total Financing Cash Outflow	64.1M	28.3M	14.3M	932,800	--
Financing Cash Flow	-64.1M	-28.3M	376.0M	-932,800	--
Net Change In Cash	-416.0M	-121.0M	251.0M	77.7M	176.0M
Ending Cash Balance	226.0M	642.0M	763.0M	512.0M	434.0M
Capex	94.9M	39.0M	176.0M	16.0M	38.3M